Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
Sign Up to like & getrecommendations! Published in 2024 at "Cancers"
DOI: 10.3390/cancers16132320
Abstract: Simple Summary The prognosis for patients with relapsed neuroblastoma is poor, and novel treatment options for these patients are needed. Some relapsed neuroblastoma tumors harbor activating mutations in the RAS/MAPK pathway. In prior studies, single… read more here.
Keywords: igf1r; ras mutated; combination; trametinib ganitumab ... See more keywords